Cross-Border Biopharma & Synthetic Biology Licensing
Targeted sourcing, asset evaluation, and bidirectional In/Out-Licensing of clinical biopharma pipelines and synthetic biology technologies.
End-to-end industrial collaboration capabilities connecting frontier therapeutic technologies with international manufacturing and market execution.
Covering the full operational chain from asset licensing and process automation to local equipment deployment.
Targeted sourcing, asset evaluation, and bidirectional In/Out-Licensing of clinical biopharma pipelines and synthetic biology technologies.
Collaborating with specialized domestic engineering partners to deliver cGMP-compliant, automated production systems ready for process validation.
Leveraging China's advanced bioprocess equipment network for equipment selection, commissioning, training, and ongoing service.
Driven by technical depth, multilingual cross-border execution, and vetted regional networks.
Leadership trained at Tsinghua University and the University of Hong Kong, with multinational operating experience across the United States, Japan, and Canada.
Fluent business and technical execution across Chinese, English, and Japanese, supported by deep Russian-speaking networks and Turkish market experience.
Specialized in cell & gene therapy (CGT), automated bioprocessing, NGS workflows, GMP facility integration, and cross-border drug In/Out-Licensing.
Deeply active across Russia, Central Asia, and the Middle East, while connecting directly with European and Asia-Pacific life science hubs.
Whether you are exploring cross-border pipeline licensing, custom automated bioprocess equipment, or supply chain integration in China, we welcome your inquiry. A managing partner for the relevant practice will respond within 3 business days.